Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/30/2024 | $4.00 | Buy | H.C. Wainwright |
| 5/30/2024 | $3.15 | Sector Outperform | Scotiabank |
| 3/24/2023 | $3.60 | Buy | Bryan Garnier |
| 1/3/2023 | $5.00 | Neutral → Buy | Guggenheim |
| 11/9/2022 | $9.00 | Neutral → Buy | Mizuho |
| 9/22/2021 | $6.00 → $7.00 | Equal-Weight | Wells Fargo |
| 9/13/2021 | $6.00 → $7.00 | Market Perform | SVB Leerink |
| 9/7/2021 | $5.00 → $6.00 | Market Perform | SVB Leerink |
4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)
SC 13G/A - Adaptimmune Therapeutics PLC (0001621227) (Subject)
SC 13D/A - Adaptimmune Therapeutics PLC (0001621227) (Subject)
SC 13G/A - Adaptimmune Therapeutics PLC (0001621227) (Subject)
Tecelra® launch on track with 9 Authorized Treatment Centers available to initiate patient treatment journey, and the first patient apheresed in Q3; expect first commercial revenues in Q4 and the number of treated patients to accelerate throughout 2025Lete-cel IGNYTE-ESO pivotal trial primary analysis reports 42% overall response rate in synovial sarcoma and myxoid/round cell liposarcoma (MRCLS); full data at CTOS conference on November 16Company restructuring to prioritize commercial sarcoma franchise and R&D programs with highest potential return on invested capital and transformational benefit to patientsPlanned 33% reduction in headcount in Q1, 2025 as part of approximately $300 million
Adaptimmune received U.S. FDA accelerated approval of Tecelra® (afami-cel), the first approved engineered cell therapy for a solid tumorPatients can begin treatment journey; biomarker testing available; Adaptimmune systems ready to receive ordersAt the end of Q2, Adaptimmune had Total Liquidity[1] of $214.8 millionPhiladelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 12, 2024) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today reports financial results and business updates for the second quarter ended June 30, 2024. The Company will host a live webcast at 8:00 a.m. EDT (1:00 p.m. BST) tod
Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy TECELRA is the first new treatment option for people with synovial sarcoma in more than a decade Adaptimmune to hold webcast at https://www.gowebcasting.com/13428 on August 2, at 8:00 a.m. EDT Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced U.S. Food and Drug Administration (FDA) accelerated approval of TECELRA® (afamitresgene autoleucel) for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*0
Tecelra® launch on track with 9 Authorized Treatment Centers available to initiate patient treatment journey, and the first patient apheresed in Q3; expect first commercial revenues in Q4 and the number of treated patients to accelerate throughout 2025Lete-cel IGNYTE-ESO pivotal trial primary analysis reports 42% overall response rate in synovial sarcoma and myxoid/round cell liposarcoma (MRCLS); full data at CTOS conference on November 16Company restructuring to prioritize commercial sarcoma franchise and R&D programs with highest potential return on invested capital and transformational benefit to patientsPlanned 33% reduction in headcount in Q1, 2025 as part of approximately $300 million
42% of people with advanced or metastatic synovial sarcoma or MRCLS had clinical responses with lete-celResults include six complete responses (6/64); twenty-one partial responses (21/64)Data to be presented at Connective Tissue Oncology Society 2024 Annual Meeting Company plans to initiate a rolling BLA submission for lete-cel for the treatment of advanced or metastatic synovial sarcoma and MRCLS by end of 2025Company to host virtual KOL event Monday, November 18, 2024; 2:30 PM EST featuring Dr. Sandra D'Angelo, M.D. (Memorial Sloan Kettering Cancer Center) - register herePhiladelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 13, 2024) - Adaptimmune Therapeutics p
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 5, 2024) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced presence and presentations at key scientific and medical conferences in November and December. Society for Immunotherapy of Cancer (SITC) 39th annual meeting, November 6-10, Houston, TXPodium presentation: "Delivering on the Promise of Cell Therapies for Solid Tumors: T-cell Therapy for Synovial Sarcoma" / Jo Brewer, PhD, Chief Scientific Officer, Adaptimmune. Scheduled for November 8, 1:45-3:20 PM CST, Session 106d: Biotech Breakthroughs – Solid Tumor IO a
10-Q - Adaptimmune Therapeutics PLC (0001621227) (Filer)
8-K - Adaptimmune Therapeutics PLC (0001621227) (Filer)
8-K - Adaptimmune Therapeutics PLC (0001621227) (Filer)
Shares of SentinelOne, Inc. (NYSE:S) shares fell sharply during Friday's session after the company posted mixed first-quarter results. SentinelOne reported quarterly losses of 23 cents per share, which missed the analyst consensus estimate of losses of 5 cents by 360%. Quarterly sales came in at $186.4 million which beat the analyst consensus estimate of $181.09 million by 2.93%, according to data from Benzinga Pro. SentinelOne shares dipped 15.9% to $16.35 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Novo Integrated Sciences, Inc. (NASDAQ:NVOS) shares jumped 130.6% to $1.04 after the company approved a $5 million stock repurchase. The comp
Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) shares are trading higher by 15.8% to $1.17 during Friday’s session after the company and Galapagos entered a clinical collaboration to license Adaptimmune’s uza-cel in head & neck cancer. Uza-cel, which has shown an 80% response rate in a Phase 1 trial, is engineered to express the CD8α co-receptor, enhancing the immune response against tumors. The collaboration will utilize Galapagos’ decentralized cell manufacturing platform, which may improve the efficacy and durability of uza-cel and enable faster treatment delivery, with a vein-to-vein time of seven days. See Also: Fed’s Preferred Inflation Gauge Matches Estimates; Personal Spe
Gainers Novo Integrated Sciences (NASDAQ:NVOS) stock moved upwards by 69.6% to $0.77 during Friday's pre-market session. The company's market cap stands at $14.5 million. Adaptimmune Therapeutics (NASDAQ:ADAP) shares moved upwards by 40.59% to $1.42. The market value of their outstanding shares is at $362.8 million. Bionomics (NASDAQ:BNOX) shares moved upwards by 29.56% to $1.28. The market value of their outstanding shares is at $13.6 million. Innovative Eyewear (NASDAQ:LUCY) shares moved upwards by 27.84% to $1.01. The market value of their outstanding shares is at $17.6 million. Xtant Medical Hldgs (AMEX:XTNT) stock moved upwards by 20.97% to $0.9. The market value of their outstandi
H.C. Wainwright initiated coverage of Adaptimmune Therapeutics with a rating of Buy and set a new price target of $4.00
Scotiabank initiated coverage of Adaptimmune Therapeutics with a rating of Sector Outperform and set a new price target of $3.15
Bryan Garnier initiated coverage of Adaptimmune Therapeutics with a rating of Buy and set a new price target of $3.60
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 31, 2024) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the third quarter ended September 30, 2024, after the US markets close on Wednesday, November 13, 2024. Following the announcement, the Company will host a live webcast at 4:30 p.m. EDT (9:30 p.m. GMT).The press release will be available in the investor section of Adaptimmune's corporate website. A live webcast and replay can be accessed at https://www.gowebcasting.com/13698. Call in information is as follows: +1-844-76
PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 04, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Dr. Joanna (Jo) Brewer as Chief Scientific Officer (CSO) effective immediately. "Jo Brewer is an exceptional scientific leader, and I am delighted that she has accepted the newly created CSO role, leading our ongoing scientific research, and developing future autologous and allogeneic therapies," said Adrian Rawcliffe, Adaptimmune's Chief Executive Officer. "Jo has a strong track record of building successful teams, driving innovation in cell therapy, as she worked on all of our autologous
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Cintia Piccina as Chief Commercial Officer effective January 31, 2022. "I am delighted to welcome Cintia to our leadership team. She brings extensive commercial experience, including in cell and gene therapy, that will be key as we prepare to submit our first BLA for afami-cel this year, and build our commercial capabilities to support the launch of this initial product and future next-gen cell therapies within our MAGE-A4 franchise. Her fresh perspective and leadership abilities will supp